에이비엘바이오

298380KOSDAQView the 제약 sectorTheme Bio & healthcare

44,700KRWMarket close of 10/20 (Tue)

Down -4.18%-1,950KRWMarket close of 10/20 (Tue)

Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/21 (Wed)46,750KRWUp +4.59%

Preliminary · just after the close · replaced by official KRX data tomorrow morning

Open
45,650
High
46,400
Low
43,700
Day range
Day range low 43,700 high 46,400, open 45,650, close 44,700, previous close 46,650
Volume
21×10K shares
9.5B KRW 0.43× the 20-session average

Market close of 10/20 (Tue)

Where it sits in the 1-year range

1-year close range 40,550 to 245,500 won, 2% up from the low

2% of the way up from the lowest close in 1 year (252 sessions) · -81.8% from the high

Something to check

1 to check: operating loss

Free · no sign-inSource from 2021-05-17

Points to check

  • Earningsto check-86.1B KRWOperating income over the last four quarters -86.1B KRW (loss)Operating income, 8 quarters
  • Daily moveusual range-4.18%-4.18%, 1.0× the usual (20-session average ±4.28%)
    That day -4.18% · usual ±4.28% · large-move threshold ±8.6%
  • Trading valueusual range0.4×9.5B KRW, 0.4× the 20-session average
    0.43× the 20-session average · check threshold 3×

The other 3 are within the usual range

  • Recent filings0Last 14 days
  • Foreign & institutional+7.1B KRWusual range
  • Data date10/20 (Tue)Market close
See the full check report

Same sector · 제약

Down -1.68%

· 29 of 168 stocks up, preferred shares excluded · trading value 827.8B KRW

Same sector · top by trading value
Stock20DChangeTrading value
셀트리온Close over the last 20 sessions +11.4%Down -0.40%139.2B KRW
삼성바이오로직스Close over the last 20 sessions -1.3%Down -2.52%129.9B KRW
삼익제약Close over the last 20 sessions -20.4%Up +2.77%76.0B KRW
녹십자엠에스Close over the last 20 sessions +30.5%Up +6.67%55.6B KRW
유한양행Close over the last 20 sessions +11.5%Down -1.37%41.6B KRW

Schedule

  • Q3 report due · 11/16 (Mon) · in 25 days
  • Next data 10/22 (Thu) after 08:50

For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.